Alan Spatz
Overview
Explore the profile of Alan Spatz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berry D, Moldoveanu D, Rajkumar S, Lajoie M, Lin T, Tchelougou D, et al.
Cell Rep
. 2025 Mar;
44(3):115365.
PMID: 40023845
Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in approximately 50%, 25%, and 15% of cutaneous melanomas, respectively. Compared to mutant BRAF and NRAS, the role of NF1...
2.
Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos M, Assad N, Batist G, et al.
Clin Cancer Res
. 2024 Dec;
31(3):439-456.
PMID: 39625818
With immuno-oncology becoming the standard of care for a variety of cancers, identifying biomarkers that reliably classify patient response, resistance, or toxicity becomes the next critical barrier toward improving care....
3.
Cohen S, Cruiziat D, Naimer J, Cohen V, Kasymjanova G, Spatz A, et al.
Curr Oncol
. 2024 Nov;
31(11):7379-7389.
PMID: 39590174
Background: Immunotherapy with ICIs has revolutionized the treatment for NSCLC. The impact of sex on treatment outcomes remains unclear. The aim of this study was to evaluate sex-related differences in...
4.
Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill R, et al.
Am J Surg Pathol
. 2024 Apr;
48(6):708-718.
PMID: 38590014
Next-generation sequencing (NGS) is increasingly being utilized as an ancillary tool for diagnostically challenging melanocytic neoplasms. It is incumbent upon the pathology community to perform studies assessing the benefits and...
5.
Agulnik J, Kasymjanova G, Pepe C, Friedmann J, Small D, Sakr L, et al.
Curr Oncol
. 2024 Mar;
31(3):1562-1571.
PMID: 38534952
The effect of COVID-19 on treatment outcomes in the literature remains limited and is mostly reported either as predictive survival using prioritization and modeling techniques. We aimed to quantify the...
6.
Husereau D, Bombard Y, Stockley T, Carter M, Davey S, Lemaire D, et al.
Curr Oncol
. 2023 Nov;
30(11):9660-9669.
PMID: 37999120
Genome-based testing in oncology is a rapidly expanding area of health care that is the basis of the emerging area of precision medicine. The efficient and considered adoption of novel...
7.
Hyrcza M, Martins-Filho S, Spatz A, Wang H, Purgina B, Desmeules P, et al.
Mod Pathol
. 2023 Nov;
37(1):100384.
PMID: 37972928
Tumor-agnostic testing for NTRK1-3 gene rearrangements is required to identify patients who may benefit from TRK inhibitor therapies. The overarching objective of this study was to establish a high-quality pan-TRK...
8.
Steinberg C, Gaudreault N, Papadakis A, Henry C, Champagne J, Philippon F, et al.
Europace
. 2023 Jun;
25(6).
PMID: 37314195
Aims: Risk stratification for sudden cardiac death in patients with Brugada syndrome remains a major challenge. Contemporary risk prediction models have only modest predictive value. The aim of this study...
9.
Moscona R, Janssen S, Elchebly M, Papadakis A, Rubin E, Spatz A
Pigment Cell Melanoma Res
. 2023 Apr;
36(3-4):299-313.
PMID: 37082838
Melanoma is the deadliest form of skin cancer, due to its tendency to metastasize early. Brother of regulator of imprinted sites (BORIS), also known as CCCTC binding factor-like (CTCFL), is...
10.
Sorin M, Camilleri-Broet S, Pichette E, Lorange J, Haghandish N, Dube L, et al.
Cancer Treat Res Commun
. 2023 Mar;
35:100696.
PMID: 36958133
Background: Lung cancer is the leading cause of cancer death in both men and women. Quebec has the highest lung cancer mortality out of all provinces in Canada, believed to...